The FDA has recently approved (emergency use authorization) two oral antivirals and a monoclonal antibody for Covid. <\/p>\n\n\n\n
The antivirals are designed for out patient use in mild to moderate Covid-19. Both have proven to be active against the original Corona virus and its new variants. <\/p>\n\n\n\n
Paxlovid uses two agents: nirmatrelvir (a viral protease inhibitor) and ritonavir (a CYP3a inhibitor). The treatment is for 5 days and can be used down to the age of 12. <\/p>\n\n\n\n
Lagevrio contains molnupiravir a nucleoside analog that can be used down to 18-year-olds but not in pregnant women. Again, it is a 5-day treatment. <\/p>\n\n\n\n
The monoclonal therapy is Evusheld and it contains two long lasting (6 months) antibodies: tixagevimab and cilgavimab. It is not a vaccine but a prophylaxis for people who are immune compromised (whether or not they have also been vaccinated) and for patients who can not receive one of the existing vaccines. <\/p>\n\n\n\n
Many immunocompromised individuals have a poor response to the vaccines and Evusheld provides an additional method of protection. <\/p>\n","protected":false},"excerpt":{"rendered":"
The FDA has recently approved (emergency use authorization) two oral antivirals and a monoclonal antibody for Covid. The antivirals are designed for out patient use in mild to moderate Covid-19. Both have proven to be active against the original Corona virus and its new variants. Paxlovid uses two agents: nirmatrelvir (a viral protease inhibitor) and ritonavir (a CYP3a inhibitor). The treatment is for 5 days and can be used down to the age of 12. Lagevrio contains molnupiravir a nucleoside…<\/p>\n